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ABSTRACT This research was conducted to evaluate the anticancer activity of new compounds of benzyl-1,10-
phenanthroline derivatives and their selectivity. In vitro anticancer activity of 11 benzyl-1,10-phenanthroline derivatives
were conducted on three human cancer cell lines, cervical cancer (HeLa), myeloma (NS-1), and breast cancer (MCF-7) using
MTT-based cytotoxicity assay. The cytotoxicity of each compoundwas assessed to normal Vero cell line by the samemethod.
The in vitro anticancer activity and cytotoxicity was expressed by the concentration inhibiting 50% of the cell growth (IC50),
and the selectivity index (SI) was determined by calculating ratio of the IC50 on Vero cell line and the human cancer cell
lines. The results showed that among the 11 compounds tested, the (1)-N-(4-butoxybenzyl)-1,10-phenanthrolinium bromide
exhibited the best in vitro anticancer activitywith an IC50 27.60± 2.76 µMonHeLa, 6.42± 5.53 µMonNS-1 and 9.44± 2.17
µM onMCF-7 cell lines. Its SI were 377.65± 39.97 on HeLa, 6158.72± 5306.34 on NS-1 and 1140.11± 261.85 onMCF-7
cell lines. This study demonstrated that (1)-N-(4-butoxybenzyl)-1,10-phenanthrolinium bromide possessed a potential in
vitro anticancer activity on cancer cell lines with high selectivity.
KEYWORDS cytotoxicity; human cancer cell lines; in vitro anticancer activity; selectivity index
1. Introduction
Many studies have been conducted to find new com-
pounds to be developed as anticancer drugs. The increased
dependence of tumor cells on iron has led to the sugges-
tion that depleting iron may be a strategy to limit tumor
growth (Huang 2003). Potent Fe chelator, 2-hydroxy-1-
naphthylaldehyde isonicotinoyl hydrazone demonstrated
selectivity against cancer cells comparedwith normal cells
in vitro (Chaston et al. 2003). Metal chelators and metal
ions have been shown to induce apoptosis through reac-
tive oxygen species (ROS) generation (Duan et al. 1999),
and act as effective antiproliferative agents (Darnell and
Richardson 1999; Gao and Richardson 2001).
The iron chelators have become a target for the de-
velopment of anticancer drugs (Richardson 2002). Iron is
one of the essential elements for existence of cancer cells.
Iron ions play an important role in several cell growth pro-
cesses, mainly the DNA synthesis. Without iron a cell can-
not finish its cycle and proceed from the G1 phase to S
(Nyholm et al. 1993; Huang 2003).
The anticancer activity of an iron chelator which
has been studied previously is desferrioxamine (DFO).
Research has proven that DFO can obstruct lymphoma
growth in animals, both in vitro (Kemp et al. 1990) and
in vivo (Kemp et al. 1995). Research has also shown
that DFO strongly obstructs neuroblastoma growth (Don-
francesco et al. 1990). However, the use of DFO is still
very limited because of its limited membrane permeabil-
ity, poor absorption from the colon, and short half life in
plasma. It also needs to be used in a long term subcuta-
neous infusion (for 12–24 hours per day and 5–6 times
per week) and is therefore costly (Richardson 2002). The
DFO also has genotoxic effects (Kim et al. 2007). As a re-
sult, recently there have been numerous attempts to iden-
tify another iron chelator which can be developed specifi-
cally for cancer treatment. One group of potential agents is
1,10-phenanthroline derivatives. The 1,10-phenantrolines
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ring system is well known for its metalloproteinase inhibi-
tion by chelating divalent metal ions. As a metal chelating
compound, 1,10-phenantroline has been used as antimi-
crobial agent againt bacterial species such as Prevotella
ruminicola, Fibrobacter succinogenes, Lachnospira mul-
tipara, and Megasphaera elsdenii wallace1996. The anti-
malarial activity of 1,10 phenanthroline was reported by
Yapi et al. (2000), and increased after blocking of the po-
tential chelating site by N-alkylation. Some compounds
of N-alkyl and N-benzyl 1,10-phenanthroline derivatives
have shown antiplasmodial activity against FCR-3 and
D10 Plasmodium falciparum (Sholikhah et al. 2006), and
antiplasmodial activity in mouse malaria models (Wi-
jayanti et al. 2006).
The antitumor activity of 1,10-phenanthroline was
reported by Sakurai et al. (1995). A derivative 1,10
phenanthroline, bis (4,7-dimethyl-1,10-phenanthroline)
sulfatooxovanadium (IV) induced apoptosis in human can-
cer cells (Narla et al. 2000), exhibited antileukemic activ-
ity with matrix metalloproteinase inhibition (Narla et al.
2001b), significant antitumor activity and delayed tumor
progression in CB.17, combined severe immunodeficient
(SCID) mouse xenograft models of human glioblastoma
and breast cancer (Narla et al. 2001a).
In the previous research, six compounds of N-
benzylated 1,10-phenanthroline derivatives were synthe-
sized and their cytotoxic activities were tested. The
N-benzylated 1,10-phenanthroline expected that they do
not have metal chelating activity. However, among
the six tested compounds, the derivatives of benzyl-
1,10-phenantroline: (1)-N-benzyl-1,10-phenanthrolinium
iodide and (1)-N-(4-benzyloxy-3-methoxybenzyl)-1,10-
phenanthrolinium chloride have cytotoxic activities with
IC50 at the myeloma cell lines of 12.15 ± 1.31 and 2.39
± 0.27 µM, and on the HeLa cell lines of 8.57 ± 0.58
and 4.85 ± 0.31µM (Sholikhah et al. 2007). It suspected
another mechanism of their anticancer activity. In a sub-
sequent research, several new compounds of benzyl-1,10-
phenanthroline derivatives have been successfully synthe-
sized. However, the anticancer activities of these syn-
thesized compounds have not yet been studied. This re-
search was conducted to evaluate the anticancer activities
of new compounds of benzyl-1,10-phenanthroline deriva-
tives upon several cancer cell lines and their selectivity.
2. Materials andmethods
2.1. Compounds Tested
There are 11 new compounds of benzyl-1,10-
phenanthroline derivatives have been synthesized
(Figure 1). Figures 1a, 1b, and 1c are the same compound
with different salt forms. Similarly, Figures 1d, 1e, and
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
FIGURE 1 Eleven derivatives of N-benzyl-1,10-phenanthroline and doxorubicin HCl: (a) (1)-N-benzyl-6-nitro-1,10-phenanthrolinium
chloride; (b) (1)-N-benzyl-6-nitro-1,10-phenanthrolinium bromide; (c) (1)-N-benzyl-6-nitro-1,10-phenanthrolinium iodide; (d) (1)-N-
benzyl-6-bromo-1,10-phenanthroliniumchloride; (e) (1)-N-benzyl-6-bromo-1,10-phenanthroliniumbromide; (f) (1)-N-benzyl-6-bromo-1,10-
phenanthrolinium iodide; (g) (1)-N-(4-methoxybenzyl)-1,10-phenanthrolinium bromide; (h) (1)-N-(4-ethoxybenzyl)- 1,10-phenanthrolinium
chloride; (i) (1)-N-(4-ethoxybenzyl)- 1,10-phenanthrolinium bromide; (j) (1)-N-(4-buthoxybenzyl)-1,10-phenanthrolinium bromide; (k) (1)-N-
(4-benzyloxy-3-methoxybenzyl)-1,10-phenanthrolinium chloride; (l) Doxorubicin hydrochloride.
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1f are the same compound, and Figures 1g and 1h are the
same compound, with different salt form. Doxorubicin
HCl (Ferron Par Pharmaceuticals, Indonesia) was used as
a positive control.
2.2. Cell lines
In vitro anticancer activity of the compounds was as-
sessed against three human cancer cell lines: a cervi-
cal cancer (HeLa) cell line, myeloma (NS-1) cell line,
and breast cancer (MCF-7) cell line which were obtained
from Integrated Research and Testing Laboratory, Uni-
versitas Gadjah Mada, Yogyakarta, Indonesia. The hu-
man cancer cell lines were maintained in vitro in RPMI-
1640 medium (Sigma-Aldrich Inc., USA), supplemented
with 7.68 mM of HEPES (Sigma Chemical Co., USA),
23.78mMof NaHCOIC3 (Sigma-Aldrich Inc., USA), con-
taining 10% fetal bovine serum (Gibco Invitrogen, USA),
2% penicillin-streptomycin (Gibco Invitrogen, USA), and
0.5% fungizone (Gibco Invitrogen, USA) in tissue culture
flask.
To determine the Selectivity Index (SI), the com-
pounds was assessed against Vero cell line obtained from
Integrated Research and Testing Laboratory, Universitas
Gadjah Mada, Indonesia. The Vero cell line was cul-
tured inM199medium (Gibco, Auckland) containing 10%
fetal bovine serum (Sigma-Aldrich, USA). Subcultures
were obtained after treatment with 0.125% trypsin (Gibco,
Auckland) in phosphate buffer saline.
2.3. In vitro anticancer activity and cytotoxicity assess-
ment
The cell was cultured in 96-well plates at 2 x 104
cells/well in 100 µL medium and were incubated in
5% CO2 incubator at 37°C for 24 h. A solution (100
µL) of a compound or doxorubicin was added at six
concentrations and were incubated for 24 h. The first
concentration of the compound 1 mg/mL was diluted
with cell medium to obtain six concentrations of the
compound. The MTT (3-(4,5dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)-based cytotoxicity assay
(Freshney 2000) was used to evaluate the in vitro anti-
cancer activity and cytotoxicity of the compounds. After
the incubation period was finished, culture medium was
taken and the cells were resuspended in new medium and
10 µL solution of 5 mg/mL of MTT (Sigma Chemical Co.,
USA) was added, then incubated for 4 h. The formation
of formazan from MTT was interrupted by adding a 100
µL of 0.04 M HCl-isopropanol. Optical density (OD) of
formazan was read by ELISA reader at λmax 550 nm. The
value of OD is directly proportional to the number of live
cells. The cell culture without tested compounds was used
as a control, considered to have 100% growth. In vitro an-
ticancer activity and cytotoxicity was expressed as IC50
which was determined by probit analysis based on the re-
lation between the concentration of the tested compound
and the percentage of cell growth inhibition. The mean
and standard deviation of the IC50 was calculated from
three replication.
2.4. Selectivity index assessment
Selectivity index of each compound was determined by
calculating the ratio of IC50 values obtained with Vero cell
line and a cancer cell line, multiplied by 100.
3. Results and discussion
3.1. In vitro anticancer activity assessment
Table 1 showed the in vitro anticancer activity of 11 com-
pounds of the 1,10-phenanthroline derivatives and doxoru-
TABLE1 IC50 ofN-benzyl1,10-phenanthrolinesderivativesoncervical cancerHeLacell line,myeloma (NS1)cell line, andbreast cancerMCF-7
cell line.
Compound IC50 (means± SEM, in µM)
HeLa cell line Myeloma (NS1)
cell line
MCF-7 cell line
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium chloride (Figure 1a) 60.86± 23.72 13.01± 4.88 11.32± 2.93
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium bromide (Figure 1b) 216.68± 59.99 58.77± 23.32 41.52± 27.14
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium iodide (Figure 1c) 232.39± 154.88 19.49± 10.45 15.65± 0.68
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium chloride (Figure 1d) 116.37± 12.70 31.73± 1.74 22.90± 4.52
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium bromide (Figure 1e) 71.83± 31.49 25.06± 1.36 17.77± 5.72
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium iodide (Figure 1f) 125.57± 50.01 33.04± 15.96 29.30± 22.62
(1)-N-(4-methoxybenzyl)- 1,10-phenanthrolinium bromide (Figure 1g) 148.87± 92.68 14.51± 0.55 49.11± 20.84
(1)-N-(4-ethoxybenzyl)- 1,10-phenanthrolinium chloride (Figure 1h) 60.07± 10.75 14.65± 8.88 10.98± 6.21
(1)-N-(4-ethoxybenzyl)- 1,10-phenanthrolinium bromide (Figure 1i) 117.36± 50.13 8.74± 1.58 87.05± 15.79
(1)-N-(4-buthoxybenzyl)- 1,10-phenanthrolinium bromide (Figure 1j) 27.60± 2.76 6.42± 5.53 9.44± 2.17
(1)-N-(4-benzyloxy-3-methoxybenzyl)- 1,10-phenanthrolinium chloride
(Figure 1k)
36.28± 7.92 8.04± 0.14 12.23± 9.89
Doxorubicine (Figure 1l) 22.39± 5.95 0.95± 0.04 3.26± 1.83
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TABLE 2 IC50 ofN-benzyl 1,10-phenanthrolines derivatives on Vero Cell Line and its selectivity index (SI).
Compound IC50 (means±
SEM, in µM)
Selectivity Index (SI)*
HeLa cell line Myeloma (NS1) cell
line
MCF-7 cell line
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium
chloride (Figure 1a)
393.84± 104.32 890.40± 336.78 4807.69± 2486.30 3728.44± 967.64
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium
bromide (Figure 1b)
452.74±167.19 226.28± 62.65 914.24± 362.79 1903.11± 1243.95
(1)-N-benzyl-6-nitro-1,10-phenanthrolinium
iodide (Figure 1c)
220.78± 26.25 170.88± 113.88 2023.82± 938.03 1412.66± 61.58
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium
chloride (Figure 1d)
177.22± 96.78 154.12± 16.82 560.12± 30.85 805.06± 159.11
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium
bromide (Figure 1e)
252.28± 30.77 434.76± 190.61 1009.39± 54.71 1584.10± 510.67
(1)-N-benzyl-6-bromo-1,10-phenanthrolinium
iodide (Figure 1f)
289.19± 60.73 302.21± 120.37 1141.14± 551.12 2443± 1887.10
(1)-N-(4-methoxybenzyl)-
1,10-phenanthrolinium bromide (Figure 1g)
188.67± 78.12 206.92± 128.82 1301.97± 49.57 468.49± 198.80
(1)-N-(4-ethoxybenzyl)-
1,10-phenanthrolinium chloride (Figure 1h)
103.80± 33.21 187.27± 40.53 1118.96± 678.03 1388.26± 784.89
(1)-N-(4-ethoxybenzyl)-
1,10-phenanthrolinium bromide (Figure 1i)
136.76± 40.78 142.53± 60.88 1617.82± 294.00 162.45± 29.47
(1)-N-(4-buthoxybenzyl)-
1,10-phenanthrolinium bromide (Figure 1j)
102.03± 16.46 377.65± 39.97 6158.72± 5306.34 1140.11± 261.85
(1)-N-(4-benzyloxy-3-methoxybenzyl)-
1,10-phenanthrolinium chloride (Figure 1k)
15.07± 15.05 43.61± 9.52 187.48± 3.41 356.34± 288.26
Doxorubicine (Figure 1l) 257.14± 82.40 1235.67± 328.50 27074.03± 1308.39 15515.44± 7849.74
* SI = IC50 Vero cell line/IC50 Cancer cell line x 100)
bicine. The in vitro anticancer activity of all the 1,10-
phenanthroline derivatives and doxorubicine is greater in
the myeloma cells and MCF-7 cells than in the HeLa cell
line. Figures 1a, 1b, and 1c are the same compound; how-
ever, they have different anion. The difference in anion
of Cl-, Br-, dan I-, the difference in ease to bind with re-
ceptor in cell lines, so that they have the difference anti-
cancer activity. According to Burger and Fiebig (2014),
a compound tested is active in anticancer screening using
cell line when the IC50 lower than 30 µM. Among those
three compounds, the compound in Figure 1a showed the
highest anticancer activity on NS-1 and MCF-7 cell lines,
and the compound Figure 1b showed no anticancer activ-
ity. The compound in Figure 1c showed a high activity on
NS-1 and MCF-7 cell lines, but no activity on HeLa cell
line. The difference cell line may cause the difference re-
ceptor for the compounds tested. So that it produces the
difference response to the compounds. Figures 1d, 1e, and
1f are the same compound, with different salt form. Sim-
ilarly with the compounds in Figures 1a, 1b, and 1c, the
difference in anion of Cl-, Br-, dan I- showed the differ-
ence in anticancer activity. Among the three compounds,
the compound in Figure 1e showed highest anticancer ac-
tivity on MCF-7 cell line. The compound in Figure 1g,
which has difference structure with the other compounds,
showed anticancer activity on NS-1 cell line. The com-
pounds in Figures 1h and Figure 1i have the same main
structure, but different salt form, and showed different ac-
tivity. The compound in Figure 1h active on NS-1 and
MCF-7 cell line, however the compound in Figure 1i is
active on NS-1 cell line only.
Among the 11 compounds, (1)-N-(4-buthoxybenzyl)-
1,10-phenanthrolinium bromide (Figure 1j) and (1)-N-
(4-benzyloxy-3-methoxybenzyl)-1,10-phenanthrolinium
chloride (Figure 1k) showed the highest anticancer
activity on NS-1 and MCF-7 cell lines. According to their
structure, these two compounds have high lipophilicity
which may cause easier to penetrate through membranes.
3.2. In vitro cytotoxicity assessment and selectivity in-
dex determination
Table 2 presents the cytotoxicity of all 11 compounds and
doxorubicine in normal Vero cell lines, and the Selectiv-
ity Index (SI) of each compound. Acccording to Popi-
ołkiewicz et al. (2005), a SI value of 100 or less would
suggest that concentration of compound for achieving ther-
apeutic effect is similar or lower than the concentration
causing toxic effects. Obviously, the most desirable sub-
stances would have SI values greater than 100.
Among the 11 compounds tested, only compound in
Figure 1k which has an SI smaller than 100, on HeLa cell
line. The other 10 compounds have higher SI than 100,
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but smaller than SI of doxorubicine as positive control.
The (1)-N-(4-buthoxybenzyl)-1,10-phenanthrolinium bro-
mide (Figure 1j) which has the highest anticancer activity
showed has an SI greater than 100.
Phenanthroline is a tricycle aromatic hydrocarbon,
with the formula C12H8N2, and it is named 1,10-
phenanthroline because two nitrogen atoms are found
at C positions 1 and 10. It is also known as ortho-
phenanthroline. The 1,10-phenanthroline is a typical
metal chelator which can bind Fe(II) and prevent the
hydroxyl radical formation which is mediated by Fe(II)
through the Fenton reaction. This substance can also
prevent DNA damage which is induced radical hydroxyl.
Phenanthroline can activate the iron binding and activity
of trans activation of DNA p53 in cancer cell of mouse in
vitro. The activation of p53 is suspected to play a role in
cell mortality because of apoptosis (Sun 1997).
The 1,10-phenantroline has been proven to have some
pharmacological activities. It has been shown to have
fungicidal and fungistatic actions, can breakdown the func-
tion of mitochondria, induce oxidative stress in yeast and
mammalian cells, and have bacteriostatic and bacterici-
dal effects (Coyle et al. 2004). Quaternary salts of 1,10-
phenantroline have studied and shown to have herbicide
and carcinostatic activity (Dumitraşcu et al. 2004).
The study of a vanadium salt of 1,10-phenantroline
has shown that derivatives of 1,10-phenantrolin have cy-
totoxic effects. Narla et al. (2000) found that compounds
with two ligand 1,10-phenantroline have greater anti-
cancer activity in low concentration. Bis(4,7-dimethyl-
1,10-phenanthroline) sulfatooxovanadium (IV) (called
METVAN) inhibit adhesion of leukemic cells on extracel-
lular matrix, has anticancer activity in cancer cell lines of
multiple myeloma, breast cancer, glioblastome, and testis
cancer (Narla et al. 2001a,b).
In this research, the chelating capacity of 1,10-
phenantroline was blocked by N-10 benzylation, so
that the 11 compounds were expected that they do
not have metal chelating activity. However, among
the 11 compounds of benzyl-1,10-phenantroline deriva-
tives tested, only 1 compound, (1)-N-benzyl-6-nitro-1,10-
phenanthrolinium bromide, has no anticancer activity.
This result showed that the metalloprotease inhibition pro-
cess is not correlated with their anticancer activity on three
cancer lines used in this research. This finding suspected
that there was another mechanism of their anticancer ac-
tivity.
4. Conclusions
The (1)-N-(4-buthoxybenzyl)-1,10-phenantrolinium bro-
mide showed the best anticancer activity and has high se-
lectivity on three cancer lines. However, its activity and se-
lectivity are still lower than doxorubicine as positive con-
trol. Further investigation is required to find new com-
pounds of benzyl-1,10-phenantrolin derivatives that have
more potent activities and which are more selective than
doxorubicine. Further studies should be conducted to eval-
uate in vivo anticancer activity in animal cancer models.
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